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Abstract
Backgrounds—In Kenya, mathematical models estimate that there are approximately 220,000 
children aged less than 15 years infected with HIV. We analyzed data from the second Kenya 
AIDS Indicator Survey (KAIS 2012) to estimate the prevalence of HIV infection among children 
aged 18 months to 14 years.
Methods—KAIS 2012 was a nationally representative 2-stage cluster sample household survey. 
We studied children aged 18 months to 14 years whose parents or guardians answered questions 
pertaining to their children by interview. Blood specimens were collected for HIV serology and 
viral load measurement.
Results—We identified 5162 children who were eligible for the study. Blood was obtained for 
3681 (71.3%) children. Among child participants, 16.4% had been tested for HIV infection in the 
past, and among children with parents or guardians who self-reported HIV-positive status, 52.9% 
had been tested for HIV infection. Twenty-eight (0.9%) children tested HIV-positive in the 
survey. Of these, 11 had been previously diagnosed with HIV infection before the survey. All 11 
children were in HIV care and receiving cotrimoxazole; 8 were on antiretorivral therapy (ART). 
Among those on ART, 4 were virologically suppressed.
Conclusions—HIV causes a substantial burden of disease in the Kenyan pediatric population. 
Although most children who had been diagnosed with HIV before the survey were engaged in care 
and treatment, they represented less than half of HIV-infected children identified in the survey. 
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Future efforts should focus on identifying infected children and getting them into care and on 
suppressive ART as early as possible.
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INTRODUCTION
Pediatric HIV infection is a worldwide public health challenge that disproportionately 
affects children in the poorest parts of the world. The Joint United Nations Programme on 
HIV/AIDS estimated that at the end of 2011, 3.4 million children younger than 15 years 
were living with HIV and that 330,000 had been newly infected in the previous year1,2; 90% 
of these children were in sub-Saharan Africa.2 Pediatric antiretroviral therapy (ART) 
coverage in low- and middle-income countries, although rapidly expanding, is relatively 
low. Worldwide, of the estimated 2 million HIV-infected children in need of ART, only 
28% have access to ART, which is substantially lower than ART coverage in adults 
(58%).2,3 In Africa, of the estimated 3.1 million children living with HIV at the end of 2010, 
1.8 million (60%) were estimated to be eligible for ART, but only 387,500 (21%) were 
receiving it.3
In Kenya, an estimated 220,000 children younger than aged 15 years were living with HIV 
in 2012.4 Despite efforts to scale-up prevention of mother-to-child transmission of HIV 
programs, almost 13,000 children were newly infected with HIV in 2011,5 and there were an 
estimated 13,000 child deaths due to HIV/AIDS.6 HIV is thought to cause 9% of all child 
mortality in Kenya,7 and many children with severe opportunistic illnesses and undiagnosed 
HIV infection continue to present to public health care facilities, as has been described 
elsewhere in Africa.8 Field experience has shown that where pediatric ART is available, the 
response to treatment of children in low-income countries is as good as that observed in 
developed countries.9 Thus, many HIV-related deaths among children living with HIV could 
be prevented through earlier diagnosis of HIV infection and early initiation of ART. 
However, despite what is known regarding the benefits of ART, treatment scale-up in the 
pediatric population has been slower than among adults in Kenya. In 2011, mathematical 
models estimated that fewer than 1 (31.1%) in 3 children who needed ART was receiving it 
compared to 8 in 10 adults.4
There are a number of reasons for this shortfall. Fear of discrimination has been shown to 
negatively affect uptake to HIV infant testing and care10–12; a recent study in Zimbabwe, for 
instance, showed that 42% of the parents/guardians feared discrimination against their 
children as a result of HIV testing.11 Other factors include lack of integration of antenatal 
prevention of mother-to-child transmission and pediatric HIV services, which limits the 
number of children accessing HIV testing in a timely manner; perceived and actual lack of 
expertise in the care of HIV-infected children; limited availability of some pediatric 
antiretroviral formulations; the complexities of using ART in the face of multiple co-
morbidities (eg, tuberculosis, malaria, malnutrition); and insufficient pediatric health care 
resources to meet the demand.13
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At the population level, HIV care and treatment comprise a cascade of interventions with 
coverage at each step dependent on coverage of the preceding step. This cascade involves 
diagnosis of HIV infection, linkage to care, determination of ART eligibility, initiation of 
ART, and successful suppression of viral replication. HIV testing is a critical first step in the 
cascade of HIV care, as well as the gateway to other prevention, treatment, and care 
interventions. However, to achieve access, reliable mechanisms must link individuals to 
needed services. Available evidence suggests considerable shortcomings with linkage and 
referral, including the lack of routine tracking mechanisms. As HIV diagnosis and treatment 
programs have scaled up in developing countries, attrition at each step in the cascade of HIV 
care has emerged as a critical concern limiting overall population-level impact for both 
adults and children.14,15 This cascade is well characterized in developed countries,16 but 
population-based estimates of pediatric HIV testing and care coverage are not available in 
most low-income countries, including Kenya.
The second Kenya AIDS Indicator Survey (KAIS 2012) was the first national survey in 
Kenya to collect HIV-specific data on children from 18 months to 14 years of age. KAIS 
2012 allowed for estimation of HIV prevalence among this population and direct assessment 
of the cascade from diagnosis of HIV infection through suppression of viral replication.
METHODS
Study Design
KAIS 2012 was a nationally representative cross-sectional survey of HIV infection and 
associated risk behavior among persons aged 18 months to 64 years, conducted from 
October 2012 to February 2013. Details of the study are described elsewhere.17 Briefly, a 
stratified 2-stage sampling design was used to select household clusters from a national 
household sampling frame, using systematic random sampling; subsequently, from the 
clusters, eligible households were selected using equal probability systematic sampling. 
Because of regional security concerns, the North Eastern region was not included in the 
sampling frame. Since half of the households selected in KAIS 2012 were required for the 
child sample, every other household was selected after random selection of the first 
household. These households were designated as child-eligible households. If a child-
eligible household did not have an eligible child aged 18 months to 14 years, the next child-
eligible household was visited until one with an eligible child was identified.
In this article, we consider all children who were aged 18 months to 14 years and resided in 
child-eligible households. Individual questionnaires were administered to consenting 
children’s parents or guardians; we refer to this as the interview sample. In child-eligible 
households, we requested permission to draw blood from eligible children for HIV serology 
and, if HIV-positive, viral load measurement. We refer to this subsample as the serological 
sample. Questions pertaining to children aged 18 months to 14 years were embedded in the 
individual questionnaire for adult women and men and were answered by parents or 
guardians. These interviews collected information on demographics and HIV testing 
histories of children residing in the household. If a child was reported as HIV-positive by the 
parent or guardian, additional information on attendance at HIV clinics, current and past use 
of ART and cotrimoxazole use was collected. Parents or guardians of children in the 
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serological sample were asked if the child had ever been tested for HIV, and if so, what the 
result of the test was.
Study Population
Our study population consisted of children aged 18 months to 14 years. Children were 
included if they were usual residents of the household or present in the household on the 
night before the survey and had their parent’s or guardian’s consent.
Measurements
The main outcome variable was HIV infection as determined by laboratory testing. 
Secondary outcomes among children with previously diagnosed HIV infection included 
attending an HIV clinic and receiving cotrimoxazole prophylaxis and ART. An additional 
outcome of interest was HIV RNA concentration among those who tested HIV-positive in 
the serological sample. We used an HIV RNA concentration threshold of <1000 copies per 
milliliter to define virologic suppression.
Laboratory Methods
We asked parents or guardians of eligible children for their verbal consent to collect a blood 
sample for biologic testing and extended storage for future unspecified testing at the 
National HIV Reference Laboratory (NHRL) in Nairobi. At NHRL dried blood spot 
specimens were tested for HIV antibody using the Vironostika HIV-1/2 UNIF II plus O 
Enzyme Immunoassay (bioMérieux SA, Marcy l’Etoile, France) and confirmed using the 
Murex HIV.1.2.O HIV Enzyme Immunoassay (DiaSorin SpA, Saluggia, Italy). Repeat 
testing was done for discordant results, and, if results remained discordant, a final 
determination was made using polymerase chain reaction for HIV antigen (Cobas Amplicor 
HIV-1 Monitor Test, version 1.5; Roche Molecular Diagnostics, Pleasanton, CA). We tested 
all confirmed HIV-positive blood specimens for HIV RNA concentration (Abbott M2000 
Real-Time HIV-1 Assay; Abbott Laboratories, Abbott Park, IL). Test results from the 
NHRL were not returned to study participants. Home-based HIV testing and counseling, 
using rapid tests according to the national HIV testing algorithm, was offered to all persons 
participating in the survey, including parents and guardians of participating children.
Statistical Analysis
We merged interview and laboratory data to produce a final survey dataset for cleaning and 
analysis. We weighted survey data to correct for unequal probability of selection and adjust 
for nonresponse. The analysis on the interview sample (ie, eligible children with available 
interview data from their parent or guardian) was restricted to describing sociodemographic 
and HIV testing characteristics. The analysis on the serological sample (ie, eligible children 
for whom we drew blood for HIV serology) included a description of socio-demographic 
characteristics, HIV testing characteristics, and for HIV-positive children, access to HIV 
care and treatment. We estimated point prevalences and 95% confidence intervals (CI). The 
Taylor Series Linearization method was used to compute variance estimates. For continuous 
variables, we calculated medians and interquartile ranges. Categorical factors associated 
with HIV infection were examined using the χ2 test, and strength of associations were 
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presented as odds ratios. We used non-normalized survey weights, based on the 2012 
population projections from the 2009 national census, to estimate the national number and 
95% CI of HIV-infected children aged 18 months to 14 years.18 SAS version 9.3 (SAS 
Institute, Cary, NC) was used for statistical analyses. Because estimates based on small 
sample sizes are not reliable and cannot be generalized to the broader population, we do not 
present weighted estimates and 95% CI for indicators based on denominators of less than 30 
observations. This includes indicators describing access to care and treatment among HIV-
infected children.
Ethical Considerations
The KAIS 2012 protocol was approved by the Kenya Medical Research Institute Ethical 
Review Committee, the US Centers for Disease Control and Prevention Institutional Review 
Board, and the Committee on Human Research of the University of California, San 
Francisco. We obtained permission from parents or guardians to draw blood and assent from 
children aged 10 years or older. Home-based HIV testing and counseling was done in a 
private location within the household. The results of home-based testing were recorded by 
the counselor in a password-protected tablet computer using the unique identification 
number for the participant. Home-based HIV test results were disclosed to parents or 
guardians.
RESULTS
In total, there were 9189 KAIS 2012 households of which 4146 were child-eligible; 5162 of 
9683 children in these households were found to be eligible. Of the 5162 eligible children, 
half (50.1%) were boys. The median age was 8.4 years (interquartile range, 4.8–11.7), and 
25.4% were aged 18 months to 4 years (Table 1). For 7.4% of children (95% CI: 6.0 to 8.7), 
1 parent had died, and for 1.3% of children (95% CI: 0.9 to 1.8), both parents had died. 
Overall 74.3% of children (95% CI: 71.2 to 77.4) resided in rural areas; the largest 
proportions were from the poorest (26.9%, 95% CI: 22.3 to 31.5) and second poorest 
(26.6%, 95% CI: 23.9 to 29.3) household wealth quintiles. Overall, 2.6% of children (95% 
CI: 1.7 to 3.5) had parents or guardians who reported an HIV-positive status.
Of the 5162 eligible children, 3681 (71.3%) children had consent obtained for the blood 
draw for HIV serology and viral load measurement in the NHRL (serological sample). 
Children who provided blood were comparable with those who did not provide blood with 
respect to most baseline characteristics assessed except for age (P < 0.0001), geographic 
region (P < 0.0001), and self-reported HIV status of the child’s parent or guardian (P = 
0.0019). Compared with children who did not provide blood, children who provided blood 
were more likely to be aged 10–14 years (42.0% vs. 31.6%); reside in Central (10.8% vs. 
5.5%), Nyanza (17.9% vs. 11.2%) and Western (16.9% vs. 9.1%) regions; and have a parent 
or guardian who self-reported HIV-positive status (3.3% vs. 1.0%), respectively (Table 1). 
Among children in the serological sample, 16.9% (95% CI: 13.8% to 20.0%) had been 
tested for HIV before the survey.
Overall, 28 (0.9%, 95% CI: 0.5 to 1.3) children tested HIV-positive in the survey (Table 2). 
HIV prevalence among girls was 1.1% (95% CI: 0.4 to 1.7) compared with 0.7% (95% CI: 
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0.3 to 1.1) among boys. Children younger than 5 years of age had a HIV prevalence of 1.6% 
(95% CI: 0.5 to 2.7) and had significantly higher odds of being HIV-positive compared with 
older children aged 10–14 years (odds ratio, 2.9, 95% CI: 1.1 to 7.5). Children whose 
parents were dead (ie, 1 or both parents) had similar HIV prevalence (0.8%, 95% CI: 0 to 
1.8) compared with children whose parents were alive (0.7%, 95% CI: 0.4 to 1.1). Children 
living in rural residences also had similar HIV prevalence compared with children living in 
urban residences (0.9%, 95% CI: 0.4 to 1.4 vs 0.8%, 95% CI: 0.1 to 1.6, respectively). High 
HIV prevalence was observed among children whose parent or guardian self-reported HIV-
positive status (6.5%, 95% CI: 2.9 to 10.2) and among children who had been tested for HIV 
infection in the past (3.2%, 95% CI: 1.3 to 5.1).
Due to the small sample size of children with laboratory-confirmed HIV infection (N = 28), 
the following section describes, in absolute numbers, select indicators in the cascade of care 
for HIV-positive children. Of the 28 children who were found to be HIV-infected in our 
sample, 11 had been previously diagnosed with HIV infection. Among these 11, all had 
attended an HIV clinic at least once before the survey and were currently taking daily 
cotrimoxazole. Eight were currently on ART and of those, 4 were virologically suppressed. 
Three of the 28 HIV-infected children were orphans with at least 1 parent who had died.
DISCUSSION
Our study provides the first population-based estimate of children living with HIV in Kenya. 
We found that the overall prevalence of HIV infection in children aged 18 months to 14 
years was 0.9%, corresponding to an estimated 104,000 HIV-infected children in this age 
group. Previous estimates on the burden of HIV among children have been measured 
indirectly through mathematical modeling.6,19 These models estimated that approximately 
200,000 children younger than 15 years were living with HIV in 2010, of whom an 
estimated 158,000 required ART. Our survey identified fewer children living with HIV 
compared to these indirect estimates. Our estimates are likely to underestimate the true 
burden of pediatric HIV infection given that our survey sampled children who had already 
survived up to 18 months. Without ART, 30% HIV-infected children are expected to die by 
1 year of age. This increases to 50% by the second year.20 Thus, our estimation of the 
burden of pediatric HIV in Kenya omits a substantial number of children who die early if no 
intervention is provided. We also found variability in the burden of HIV among children, 
with a decrease in HIV prevalence with increasing age. This is consistent with the likely 
high mortality in the infected pediatric population in Africa from earlier birth cohorts.20,21 
Orphanhood was much lower than that reported in previous studies, which have estimated 
that about 45% of children with HIV infection will be orphaned,22,23 but selective mortality 
among children and their parents may have led to our lower estimates. Another possibility is 
that the scale-up of ART for adults may have resulted in more parents surviving. Also the 
proportion of orphans in our study could be an underestimation considering that children 
whose parents’ status was unknown may have been orphaned.
Only 16% of children were reported to have had a previous HIV test, and less than half of 
children with HIV-infected parents or guardians had ever been tested for HIV. Our study 
also confirmed that most children who were living with HIV remained undiagnosed and 
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unable to access care and treatment. Although significant progress has been made in scaling 
up HIV testing for adults,24 these findings highlight the need to improve testing strategies 
for children. The high proportion of undiagnosed HIV infection, particularly among those 
children whose parents or guardians were infected, underscores the magnitude of missed 
opportunities for diagnosis of HIV infection. Expansion of family testing strategies in 
facility and community-based settings can help to rapidly increase identification of HIV-
infected children and link them into care.25
We were encouraged to find that all children in the sample who had been previously 
diagnosed with HIV infection had accessed HIV care and had started cotrimoxazole 
prophylaxis. Nonetheless, that only 8 of 28 children with laboratory-diagnosed HIV 
infection were receiving ART should be a cause for concern. In addition, only half of 
children who were currently on ART were virologically suppressed. This was lower than 
proportions reported in other studies in Kenya where the estimated proportion of children 
who were able to achieve and maintain virologic suppression was around 70%.25,26 Because 
we did not assess the duration of ART for these children, it is possible that some of these 
children may have initiated ART recently and therefore not yet achieved viral suppression.
Our study had several limitations. Although the majority of childhood infections are likely 
to occur in children younger than aged 18 months, we chose to survey only children from 18 
months of age because of the complicated logistics of RNA testing in the field and returning 
results for these children after survey teams had left the cluster. Therefore, our estimates are 
not generalizable to all children. The details of medical histories were obtained from 
mothers and other caregivers, and we were unable to confirm these data by chart review, 
introducing the potential for recall bias. Finally, although this was a national household 
survey, we were only able to identify 28 HIV-infected children. Based on this small sample 
size, some of our estimates are imprecise and not generalizable to the broader population. 
Caution should therefore be used when interpreting reported indicators of care and treatment 
among HIV-infected children.
Despite these limitations, KAIS 2012 is the first survey to provide direct estimates of HIV-
related indicators for children, information that program managers and policy makers can 
use immediately to inform pediatric programs for HIV prevention, care, and treatment. HIV 
causes a substantial burden of disease in the pediatric population in Kenya. Future efforts 
should focus on expanded testing of children to identify HIV-infected children and getting 
them into care and on suppressive ART as early as possible.
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